More attention for high-risk pathological features for stage Ⅱ colorectal cancer required.
10.3760/cma.j.cn112151-20230508-00321
- VernacularTitle:要关注Ⅱ期结直肠癌的高危病理因素
- Author:
Y F WANG
1
;
W C XUE
2
Author Information
1. Department of Pathology, Colorectal Cancer Center of Peking University Shougang Hospital, Beijing 100144, China.
2. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pathology, Peking University Cancer Hospital and Institute, Beijing 100142, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Colorectal Neoplasms/pathology*;
Risk Factors;
Chemotherapy, Adjuvant;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Neoplasm Staging;
Prognosis
- From:
Chinese Journal of Pathology
2023;52(8):773-777
- CountryChina
- Language:Chinese
-
Abstract:
Stage Ⅱ (T3-4N0M0) accounts for 25% of colorectal cancer and five-year survival is between 70% and 80%. However, 25% of patients develop distant metastases and have a survival rate similar to that of stage Ⅲ disease. However, whether or not to give adjuvant chemotherapy is still a controversial issue. As a result, there has been a lot of interest in the identification of the pathological factors underlying the poor prognosis associated with this stage, in order to establish a firmer basis for the administration of adjuvant chemotherapy. But not all high-risk factors are equal for stage Ⅱ colorectal cancer, variability still exists in the management and outcomes of high-risk patients. Here be introduced and commented on thinking and understanding about its controversy and evolution for the attention of the working pathologist and gastroenterologist doctors.
